Results 1 to 10 of about 45,446 (119)
Chromosomal Heterogeneity and Enrichment of Mitotic Regulatory Programs Reveal a Therapeutic Vulnerability in Cytarabine-Resistant FLT3-ITD AML [PDF]
Current Issues in Molecular BiologyCytarabine is a cornerstone of acute myeloid leukemia (AML) therapy; however, acquired resistance remains a major clinical challenge. FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD), a common genetic alteration in AML, is associated ...
Jui-Hung Yen +6 more
doaj +2 more sources
Effect of Rutin on Cytarabine-Associated Pulmonary Oedema and Oxidative Stress in Rats [PDF]
Anais da Academia Brasileira de Ciências, 2020 Cytarabine is effectively used in the treatment of adult acute leukemia, but it has a dose-limiting side effect of fatal pulmonary oedema because it increases the vascular permeability of the alveolar capillaries.
ASLI O. BILGIN +8 more
doaj +1 more source
Interaction of Lipophilic Cytarabine Derivatives with Biomembrane Model at the Air/Water Interface
Membranes, 2022 Cell membrane models are useful for obtaining molecular-level information on the interaction of biologically active molecules whose activity is believed to depend also on their effects on the membrane.
Jhon Fernando Berrio Escobar +4 more
doaj +1 more source
HemaSphere, 2022 Resistance to cytarabine is a key problem in the treatment of acute myeloid leukemia (AML). To understand the molecular biology of resistance to cytarabine, a viability-based chemosensitizer screen was utilized. We screened synthetic lethal targets using
Miriam Rehberger +7 more
doaj +1 more source
The bioavailability of cytarabine in dogs with meningoencephalitis of unknown etiology through iontophoresis and rectal delivery [PDF]
Open Veterinary Journal, 2021 Background: Cytarabine (CA) is used to treat dogs with meningoencephalitis of unknown etiology (MUE) by subcutaneous (SC) or intravenous (IV) administration.
Shelby L. Mancini +5 more
doaj +1 more source
Results in Chemistry, 2023 The present studies used biophysical techniques to examine the binding interaction mechanism of cytarabine anticancer drugs with human serum albumin (HSA) and checkpoint kinase 1.
Manoharan Rupavarshini +10 more
doaj +1 more source
Nanomaterials, 2022 Innovative drug delivery systems based on iron oxide nanoparticles (INPs) has generated a lot of interest worldwide and have prime biomedical benefits in anticancer therapy.
Ritesh Fule +8 more
doaj +1 more source
Orphanet Journal of Rare Diseases, 2022 Background Non-Langerhans cell histiocytosis, including Erdheim–Chester disease (ECD), Rosai–Dorfman disease (RDD), indeterminate cell histiocytosis (ICH), and unclassified histiocytosis, is a rare disorder lacking a standard treatment strategy.
Ting Liu +7 more
doaj +1 more source
Frontiers in Oncology, 2020 Background: The role of cytarabine on newly diagnosed primary central nervous system lymphoma (PCNSL) remains controversial. The present study mainly aimed to assess the efficacy and safety of cytarabine in the induction treatment of PCNSL.Methods: We ...
Xiaohong Zheng +4 more
doaj +1 more source
Cell Death and Disease, 2022 Venetoclax plus cytarabine therapy is approved for elderly acute myeloid leukemia (AML) patients and needs further improvement. We studied the mechanisms of venetoclax plus cytarabine treatment and searched for a third agent to enhance their effects ...
Jingyi Zhang +7 more
doaj +1 more source